SKYE News and Press, Skye Bioscience Inc Com From 08/09/21

OTCQB Venture Company Investor Presentations Now Available for On-Demand Viewing Canada NewsWire Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations NEW YORK , Aug. 9, ...

Executive Presentations at Live Virtual Small Cap Growth Investor Conference: Thursday August 5th Canada NewsWire Company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , Aug. 3, 2021 /CNW/ - Vir...

Live Investor Conference & Webinar: OTCQB Venture Conference on August 5th Live Investor Conference & Webinar: OTCQB Venture Conference on August 5th Company executives will share vision and answer audience questions at VirtualInvestorConferences.com PR Newswire ...

SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant...

Cannabis Industry Investor Presentations Now Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations PR Newswire NEW YORK , July 1, 2021 /PRNe...

Cannabis Industry Investor Conference: Company Executives Present June 29th & 30th Cannabis Industry Investor Conference: Company Executives Present June 29th & 30th Canada NewsWire Cannabis Company Executives share vision, answer questions live at Virtua...

SAN DIEGO, CA, June 10, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant...

THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average IOP reduction of 26.5% at 9 hours, significantly better than any single drug or combination tested THCVHS demonstrates superior ...

Novel glaucoma drug ready for next devel opment phase - GLP toxicology study – on critical path to first human clinical trial Ongoing development of THCVHS includes near-term preclinical comparison with and in combination with leading g...

LOS ANGELES, CA / ACCESSWIRE / April 19, 2021 / The Planet MicroCap Showcase will take place on April 20-22, 2021, where 66 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience. The Planet MicroCap Showcase: VIRTU...